A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Authors
Keywords
-
Journal
EUROPEAN RESPIRATORY JOURNAL
Volume 53, Issue 3, Pages 1801992
Publisher
European Respiratory Society (ERS)
Online
2019-02-14
DOI
10.1183/13993003.01992-2018
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
- (2018) Thida Win et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Quantification of Lung PET Images: Challenges and Opportunities
- (2017) Delphine L. Chen et al. JOURNAL OF NUCLEAR MEDICINE
- An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study
- (2017) Toby M Maher et al. Lancet Respiratory Medicine
- A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
- (2017) A. J. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- Profibrotic up-regulation of glucose transporter 1 by TGF-β involves activation of MEK and mammalian target of rapamycin complex 2 pathways
- (2016) Mahefatiana Andrianifahanana et al. FASEB JOURNAL
- Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
- (2016) Paul F Mercer et al. THORAX
- Pharmacologic inhibition of lactate production prevents myofibroblast differentiation
- (2015) Robert Matthew Kottmann et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
- (2015) E Geuna et al. BRITISH JOURNAL OF CANCER
- Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis
- (2015) Harold R. Collard EUROPEAN RESPIRATORY JOURNAL
- A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
- (2015) Johanna C. Bendell et al. INVESTIGATIONAL NEW DRUGS
- Improved correction for the tissue fraction effect in lung PET/CT imaging
- (2015) Beverley F Holman et al. PHYSICS IN MEDICINE AND BIOLOGY
- Revealing the Pathogenic and Aging-related Mechanisms of the Enigmatic Idiopathic Pulmonary Fibrosis. An Integral Model
- (2014) Moisés Selman et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
- (2014) Phillip L. Molyneaux et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis
- (2014) Peter Norman EXPERT OPINION ON THERAPEUTIC PATENTS
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- (2014) Talmadge E. King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Future Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop Report
- (2013) Timothy S. Blackwell et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Lactic Acid Is Elevated in Idiopathic Pulmonary Fibrosis and Induces Myofibroblast Differentiation via pH-Dependent Activation of Transforming Growth Factor-β
- (2012) Robert Matthew Kottmann et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
- (2012) Irene Brana et al. BMC Medicine
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
- (2011) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- The importance of correction for tissue fraction effects in lung PET: preliminary findings
- (2011) Tryphon Lambrou et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials
- (2011) Thida Win et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Idiopathic pulmonary fibrosis
- (2011) Talmadge E King et al. LANCET
- Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry
- (2011) Jonathan Clark et al. NATURE METHODS
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Collaborative Radiologic and Histopathologic Assessment of Fibrotic Lung Disease
- (2010) Jeffrey R. Galvin et al. RADIOLOGY
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- Idiopathic Pulmonary Fibrosis and Diffuse Parenchymal Lung Disease: Implications from Initial Experience with 18F-FDG PET/CT
- (2009) A. M. Groves et al. JOURNAL OF NUCLEAR MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started